Pleiotropic effects of rosuvastatin Review article
Article Sidebar
Published:
Sep 30, 2015
Keywords:
rosuvastatin, pleiotropic effects
Main Article Content
Abstract
Rosuvastatin is the most effective statin as far as LDL level reduction is concerned. Despite its very strong hypolipidemic effect, rosuvastatin is tolerated as well as other, weaker hypolipidemic drugs. In addition, rosuvastatin has large spectrum of lipid-independent effects. It leads to stabilization of atherosclerotic plaques, decreases systemic inflammatory parameters and influences haemostasis. Moreover, rosuvastatin possesses nefroprotective properties. Pleiotropic effect of rosuvastatin is one of the major arguments for wide use of this particular statin in the treatment of dyslipidemia.
Article Details
How to Cite
Wełnicki , M., & Mamcarz , A. (2015). Pleiotropic effects of rosuvastatin. Medycyna Faktow (J EBM), 8(3(28), 60-63. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2298
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zdrojewski T., Bandosz P., Gaciong Z. et al. w imieniu Komitetu Naukowego Programu NATPOL 2011. Konferencja prasowa Centrum PAP, 14 września 2011 r.
2. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32: 1769-1818.
3. Bartkowiak R., Janion M., Wożakowska-Kapłon B.: Plejotropowe mechanizmy działania statyn. Znaczenie w leczeniu chorób serca i naczyń. Via Medica 2001, Forum Kardiologów 2001; 6(2).
4. Galus R., Zandecki Ł., Jóźwiak J. et al.: Pozalipidowe działanie statyn. Pol. Merk. Lek. 2008; XXIV(144): 545.
5. Gąsior M., Czekaj A.D., Przybylska K. et al.: Plejotropowe działanie statyn. Choroby Serca i Naczyń 2008; 5(3): 141-145.
6. Śliż D., Mamcarz A., Filipiak K.J. et al.: 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol. Arch. Med. Wewn. 2010; 120(9): 328-333.
7. Wełnicki M., Folga A., Sudoł K., Mamcarz A.: Polskie badanie skuteczności leczenia hipercholesterolemii – analiza wyników badania CEPHEUS. Polski Przegląd Kardiologiczny 2014; 16(1): 5-11.
8. Filipiak K.J., Cybulska B., Dudek D. et al.: Aktualne problemy terapii dyslipidemii w Polsce – Deklaracja Sopocka. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń 2011; 8(1): 1-4.
9. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [online].
10. Jones P.H., Davidson M.H., Stein E. et al.: Comparison of safety and efficacy of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin across doses (STELLAR trial). Am. J. Cardiol. 2003; 92: 152-160.
11. Barylski M.: Rosuwastatyna. Biblioteka pisma „Cardiology Journal”. Via Medica, Gdańsk 2010.
12. Shepherd J., Vidt D.G., Miller E. et al.: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107: 433-443.
13. Ridker P.M., Danielson E., Fonseca F.A.H. et al. for the JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-2207.
14. Ridker P.M., MacFadyen J., Cressman M. et al.: Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention – an Intervention Trial Evaluating Rosuvastatin) trial. J. Am. Coll. Cardiol. 2010; 55(12): 1266-1273.
15. Glynn R.J., Danielson E., Fonseca F.A. et al.: A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009; 360: 1851-1861.
16. Robinson J.G., Smith B., Maheshwari N., Schrott H.: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 2005; 46(10): 1855-1862.
17. Betteridge D.J., Gibson J.M., on behalf of the ANDROMEDA Study Investigators: Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet. Med. 2007; 24: 541-549.
18. Berne C., Siewert-Delle A.; URANUS study investigators: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study Cardiovasc. Diabetol. 2005; 4: 7.
19. Sorof J., Berne C., Siewert-Delle A. et al., on behalf of the URANUS study investigators: Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Research and Clinical Practice 2006; 72: 81-87.
20. Ballantyne C.M., Bertolami M., Hernandez Garcia H.R. et al.: Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am. Heart J. 2006; 151: 975.e1-9.
21. Crouse R.J., Raichlen J.S., Ward A. et al. for the METEOR Study Group: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-1353.
22. Ma Q., Zhou Y., Zhai G. et al.: Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Angiology 2015 Aug 13. pii: 0003319715599863. [Epub ahead of print].
23. Yang Y., Wu Y.X., Hu Y.Z.: Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) 2015; 94(30): e1226.
24. Ozguler I.M., Burma O., Uysal A., Akbulut H.: Rosuvastatin Lowers Systemic Inflammatory Response in Coronary Artery Bypass Graft Accompanied by Cardiopulmonary Bypass Surgery: A Randomized Controlled Study. Clin. Invest. Med. 2015; 38(4): E154-63.
2. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32: 1769-1818.
3. Bartkowiak R., Janion M., Wożakowska-Kapłon B.: Plejotropowe mechanizmy działania statyn. Znaczenie w leczeniu chorób serca i naczyń. Via Medica 2001, Forum Kardiologów 2001; 6(2).
4. Galus R., Zandecki Ł., Jóźwiak J. et al.: Pozalipidowe działanie statyn. Pol. Merk. Lek. 2008; XXIV(144): 545.
5. Gąsior M., Czekaj A.D., Przybylska K. et al.: Plejotropowe działanie statyn. Choroby Serca i Naczyń 2008; 5(3): 141-145.
6. Śliż D., Mamcarz A., Filipiak K.J. et al.: 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol. Arch. Med. Wewn. 2010; 120(9): 328-333.
7. Wełnicki M., Folga A., Sudoł K., Mamcarz A.: Polskie badanie skuteczności leczenia hipercholesterolemii – analiza wyników badania CEPHEUS. Polski Przegląd Kardiologiczny 2014; 16(1): 5-11.
8. Filipiak K.J., Cybulska B., Dudek D. et al.: Aktualne problemy terapii dyslipidemii w Polsce – Deklaracja Sopocka. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń 2011; 8(1): 1-4.
9. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [online].
10. Jones P.H., Davidson M.H., Stein E. et al.: Comparison of safety and efficacy of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin across doses (STELLAR trial). Am. J. Cardiol. 2003; 92: 152-160.
11. Barylski M.: Rosuwastatyna. Biblioteka pisma „Cardiology Journal”. Via Medica, Gdańsk 2010.
12. Shepherd J., Vidt D.G., Miller E. et al.: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107: 433-443.
13. Ridker P.M., Danielson E., Fonseca F.A.H. et al. for the JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-2207.
14. Ridker P.M., MacFadyen J., Cressman M. et al.: Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention – an Intervention Trial Evaluating Rosuvastatin) trial. J. Am. Coll. Cardiol. 2010; 55(12): 1266-1273.
15. Glynn R.J., Danielson E., Fonseca F.A. et al.: A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009; 360: 1851-1861.
16. Robinson J.G., Smith B., Maheshwari N., Schrott H.: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 2005; 46(10): 1855-1862.
17. Betteridge D.J., Gibson J.M., on behalf of the ANDROMEDA Study Investigators: Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet. Med. 2007; 24: 541-549.
18. Berne C., Siewert-Delle A.; URANUS study investigators: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study Cardiovasc. Diabetol. 2005; 4: 7.
19. Sorof J., Berne C., Siewert-Delle A. et al., on behalf of the URANUS study investigators: Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Research and Clinical Practice 2006; 72: 81-87.
20. Ballantyne C.M., Bertolami M., Hernandez Garcia H.R. et al.: Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am. Heart J. 2006; 151: 975.e1-9.
21. Crouse R.J., Raichlen J.S., Ward A. et al. for the METEOR Study Group: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-1353.
22. Ma Q., Zhou Y., Zhai G. et al.: Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Angiology 2015 Aug 13. pii: 0003319715599863. [Epub ahead of print].
23. Yang Y., Wu Y.X., Hu Y.Z.: Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) 2015; 94(30): e1226.
24. Ozguler I.M., Burma O., Uysal A., Akbulut H.: Rosuvastatin Lowers Systemic Inflammatory Response in Coronary Artery Bypass Graft Accompanied by Cardiopulmonary Bypass Surgery: A Randomized Controlled Study. Clin. Invest. Med. 2015; 38(4): E154-63.